The cost of healthcare has become so great that it's important to review the evidence to determine whether the drug is a good value for the money. Yet, pharmacoeconomics is rarely included in the decision process.
Q&A: Bryan R. Luce
Advertisement
Articles by Q&A: Bryan R. Luce
Advertisement
Latest Updated Articles
Marketing to Professionals: Shaping the Future of MedicarePublished: July 1st 2005 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Merck Planning $70 Billion Investment for US Expansion
2
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
3
From Advantage to Essential: How Daily Data & AI Alerts Transform Commercial Functions
4
Navigating the Complexities of a Global Pharma Expansion
5
